Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) received a $12.00 price target from equities research analysts at Aegis in a report released on Monday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Aegis’ price objective suggests a potential upside of 72.17% from the stock’s previous close.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 6.97 on Monday. Corbus Pharmaceuticals Holdings has a 1-year low of $1.01 and a 1-year high of $7.88. The company has a 50-day moving average price of $4.30 and a 200 day moving average price of $2.98. The company’s market capitalization is $304.92 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative return on equity of 107.10% and a negative net margin of 890.44%. Equities research analysts anticipate that Corbus Pharmaceuticals Holdings will post ($0.40) EPS for the current year.

In other Corbus Pharmaceuticals Holdings news, CFO Sean F. Moran purchased 17,900 shares of the firm’s stock in a transaction that occurred on Friday, August 26th. The stock was bought at an average cost of $3.92 per share, with a total value of $70,168.00. Following the completion of the transaction, the chief financial officer now owns 299,310 shares of the company’s stock, valued at approximately $1,173,295.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sean F. Moran purchased 148,960 shares of the firm’s stock in a transaction that occurred on Thursday, August 18th. The shares were acquired at an average cost of $3.32 per share, with a total value of $494,547.20. Following the completion of the transaction, the chief financial officer now directly owns 216,410 shares of the company’s stock, valued at approximately $718,481.20. The disclosure for this purchase can be found here. 11.60% of the stock is owned by insiders.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.